EZH2 and non-small cell lung carcinoma: Moreover, in the same study performed (Zhang Q. et al., 2024), a novel inhibitor which targets not only EZH2, but also G9a, was developed to reverse to cisplatin, paclitaxel or erlotinib resistance in NSCLC, named SU08.